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ORIGINAL ARTICLE
The carrier rate of hepatitis B surface antigen
(HBsAg) in the general population of Taiwan was
as high as 15–20% before the mass vaccination
program was implemented.1,2 Hepatitis B virus
(HBV) infection was believed to cause 80% of
adult-onset and nearly 100% of childhood cases
of hepatocellular carcinoma (HCC) in Taiwan.3–5
Therefore, the Taiwan government launched a
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Background/Purpose: The nationwide hepatitis B vaccination program in Taiwan was well known for its
efficacy in reducing the carrier rate of hepatitis B and the morbidity and mortality of hepatitis B-related dis-
eases among children. The aim of this study was to investigate the seroprevalence of hepatitis B 20 years after
this program was implemented.
Methods: A total of 7592 freshmen from one university in Northern Taiwan participated in this study during
their school entry health exam in September 2003 and September 2004. Basic data including gender,
birthday, family history and vaccination history of hepatitis B by self-reported questionnaire were collected.
Hepatitis B serum markers, including hepatitis B surface antigen, antibody against hepatitis B surface antigen,
and antibody against hepatitis B core antigen were all checked. The differences in the seroprevalence of
hepatitis B between two groups of subjects born before July 1984 and after July 1984 were examined. Multiple
logistic analyses were performed for identifying the odds ratio (OR) of family history and other variables for
each hepatitis B serum marker.
Results: Subjects born after July 1984 were found to have a lower rate of hepatitis B surface antigen of 2.2%
(95% confidence interval [CI], 1.8–2.6%) vs. 7.4% (95% CI, 5.9–8.9%), and core antibody against hepatitis
B of 6.7% (95% CI, 6.0–7.3%) vs. 23.5% (95% CI, 21.1–25.9%), but a higher rate of surface antibody against
hepatitis B of 74.3% (95% CI, 73.2–75.4%) vs. 69.1% (95% CI, 66.5–71.7%) compared with those born
before July 1984 (all p < 0.001). Subjects with a family history of hepatitis B had higher risk of being infected
by hepatitis B (OR, 4.07; 95% CI, 3.18–5.12) and becoming carriers (OR, 7.26; 95% CI, 5.05–10.44) after
adjustment for sex, age, birth year, and self-reported hepatitis B vaccination history.
Conclusion: The seroprevalence of hepatitis B surface antigen continued to decline 20 years after neonatal
hepatitis B vaccination program. It is strongly recommended that those who have a family history of hepatitis
B should receive early check-up of hepatitis B status after complete vaccination or closely follow up their
hepatitis B status after neonatal hepatitis B vaccination. [J Formos Med Assoc 2007;106(7):513–519]
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nationwide hepatitis B vaccination program in
July 1984. For the first 2 years, the program cov-
ered only neonates born to HBsAg-carrier mothers,
but was later extended to cover all neonates by
July 1986.6,7 As a result, the carrier rate of HBsAg
among children declined gradually as time went
on.8,9 The incidence of HCC in children aged
6–14 years and the corresponding rates of mortal-
ity from HCC also decreased.10 Further, the mortal-
ity rate from fulminant hepatitis in children also
decreased.11,12 In a survey performed 15 years after
nationwide vaccination had begun, more than
85% of all children had received at least three
doses of the HBV vaccine. The decrease in HBV
infection rate and HBsAg carrier rate was demon-
strated 15 years after the launch of this nationwide
vaccination program.13 It has now been 20 years
since the initiation of this program; thus, this
study aimed to assess the seroprevalence of HBV
serum markers 20 years after the implementation
of the HBV vaccination program.
Subjects and Methods
Subjects
The studied university is a general university lo-
cated in Taipei, Northern Taiwan. Freshmen were
requested to receive routine school entry health
examination at the beginning of the first semes-
ter, in September every year. For this study, those
who entered the university in 2003 and 2004 were
included since these students had been born just
near the start of the mass HBV vaccination pro-
gram in Taiwan. However, any students who were
foreigners or who came from overseas were ex-
cluded from this study. All of the study subjects
signed informed consent forms witnessed by the
school health committee and the ClinicalTrials.gov
identifier is NCT00173940.
Measures
Physical examinations, questionnaires, and blood
tests were performed by medical staff from the uni-
versity hospital and university health center. Basic
data including gender, birthday, family history and
vaccination history of hepatitis B by self-reported
questionnaire were collected. HBV serum markers,
including HBsAg, antibody against hepatitis B sur-
face antigen (anti-HBs), and antibody against hep-
atitis B core antigen (anti-HBc) were all checked.
The central laboratory of the university hospital
changed some machines and kits in 2004. All
serum samples in this study were checked for
anti-HBc by microparticle enzyme immunoassay
(AxSYM; Abbott, Germany). The other two serum
markers, HBsAg and anti-HBs, were checked by
enzyme immunoassay (BepIII; DADE Behring,
Germany) for freshmen in 2003, and by micro-
particle enzyme immunoassay (AxSYM; Abbott)
for freshmen in 2004. Samples with anti-HBs
< 10 mIU/mL were interpreted as non-reactive.
Throughout the study, we took HBsAg to be the
marker of the chronic carrier stage, anti-HBs to be
the marker of immunity, either from vaccination
or infection, and anti-HBc to be the marker of past
infection. Seronegativity was defined as being neg-
ative for all three hepatitis B markers HBsAg, anti-
HBs and anti-HBc. With regards to anti-HBs(+),
we took anti-HBs(+) and anti-HBc(–) to be mark-
ers of vaccination, whereas anti-HBs(+) and anti-
HBc(+) were markers of past infection. We defined
family history of hepatitis B as having any family
members who have HBsAg positivity.
Statistical analysis
SAS version 9.1 (SAS Institute Inc., Cary, NC, USA)
was used for statistical analysis. The differences
in the seroprevalence of hepatitis B between the
two birth groups were examined by χ2 test. Mul-
tiple logistic analyses were performed for identi-
fying the odds ratio (OR) of family history and
other variables for hepatitis B serum markers. A 
p value less than 0.05 was considered statistically
significant.
Results
A total of 8473 freshmen entered the university
in 2003 or 2004 and received the entrance health
examination; 881 foreigners, overseas students and
subjects with incomplete data were excluded.
Therefore, 7592 freshmen were included in the
analysis; 6388 (84.1%) subjects were born after
July 1, 1984. Most of them (5805, 90.9% of sub-
jects born after July 1, 1984) were born during
the first 2 years of the mass vaccination program.
The male to female sex ratio was 1.15, and mean
age was 19.8 ± 2.7 years (range, 16.1–54.2 years).
The majority (5135, 67.6%) of subjects reported
previous hepatitis B vaccination history, and 661
(8.7%) subjects reported family history of hepa-
titis B (Table 1).
The prevalence of positive HBsAg, positive anti-
HBs and positive anti-HBc among freshmen were
3.0% (95% confidence interval [CI], 2.6–3.4%),
73.5% (95% CI, 72.5–74.5%) and 9.3% (95% CI,
8.7–10.0%), respectively. The frequency distribu-
tion and 95% CIs of the HBV markers for freshmen
born before July 1984 and after July 1984 are
shown in Table 2. Compared with the subjects who
were born before July 1984, the freshmen born
after July 1984 had a lower rate of HBsAg seropos-
itivity of 2.2% (95% CI, 1.8–2.6%) vs. 7.4% (95%
CI, 5.9–8.9%) and anti-HBc seropositivity of
6.7% (95% CI, 6.0–7.3%) vs. 23.5% (95% CI,
21.1–25.9%), but a higher rate of anti-HBs
seropositivity of 74.3% (95% CI, 73.2–75.4%)
vs. 69.1% (95% CI, 66.5–71.7%) (all p < 0.001).
Among freshmen born before 1984 with anti-HBs
antibody, 77.5% (95% CI, 74.7–80.4%) were
found to be anti-HBc negative. The prevalence 
of seronegativity for all three HBV serum markers
was similar in the two groups: 23.2% (95% CI,
22.2–24.2%) vs. 22.8% (95% CI, 20.5–25.2%).
All seronegative subjects were classified into
subgroups according to birth year and self-
reported vaccination history. The seronegative rate
was 21.5% in subjects with self-reported hepatitis B
vaccination history, and 38.9% in those without
self-reported hepatitis B vaccination history. In
addition, the seronegative rate of subjects born
before July 1984 and after July 1984 was 19.2%
and 21.8% in subjects with self-reported hepatitis B
vaccination history, and 33.5% and 41.5% in those
without self-reported hepatitis B vaccination his-
tory, respectively (p < 0.001).
Multiple logistic regression analyses were per-
formed to determine the association of hepatitis B
family history and HBsAg seropositivity among
freshmen (Table 3). After adjusting for gender, age,
Serostatus of hepatitis B among freshmen
J Formos Med Assoc | 2007 • Vol 106 • No 7 515
Table 1. Characteristics of the study population
Total Before July 1984 After July 1984
Characteristics
n (%) n (%) n (%)
p
Year of school entry < 0.0001
2003 3813 (50.2) 820 (68.1) 2993 (46.9)
2004 3779 (49.8) 384 (31.9) 3395 (53.1)
Sex 0.02
Female 3539 (46.6) 525 (43.6) 3014 (47.2)
Male 4053 (53.4) 679 (56.4) 3374 (52.8)
Family history of hepatitis B* 0.9
Yes 661 (8.7) 106 (8.8) 555 (8.7)
No 6926 (91.2) 1098 (91.2) 5828 (91.2)
Unknown or not available 5 (0.1) 0 (0.0) 5 (0.1)
Self-reported vaccination history < 0.0001
Yes 5135 (67.6) 657 (54.6) 4478 (70.2)
No 501 (6.6) 161 (13.4) 340 (5.3)
Unknown or not available 1956 (25.8) 386 (32.1) 1565 (24.5)
Total 7592 (100.0) 1204 (15.9) 6388 (84.1)
*Family history of hepatitis B refers to any family members who have HBsAg positivity.
birth year, and self-reported hepatitis B vaccination
history, subjects with family history of hepatitis B
were found to have 7.26 times (95% CI, 5.05–
10.44) higher risk of HBsAg positivity, 4.07 times
(95% CI, 3.18–5.21) higher risk of anti-HBc posi-
tivity, and 0.63 times (95% CI, 0.52–0.77) risk of
anti-HBs positivity compared with those without
family history of hepatitis B (p < 0.001).
Discussion
Previous studies have disclosed the significant
decrease in HBsAg carriers and anti-HBc seropos-
itivity among children and adolescents after the
mass hepatitis B vaccination program.6,9,14–16 This
study, an epidemiologic survey extending over
20 years after the introduction of hepatitis B vacci-
nation, adds additional information regarding the
changing pattern of hepatitis B following vaccina-
tion in a previously hyperendemic country. The
participants in the present study included freshmen
who lived across Taiwan, thus they could be con-
sidered to be a distributed sample of the general
population at about 20 years old. The main results
delineated a significant decrease of both HBsAg
and anti-HBc antibody as markers of HBV infec-
tion in students born after the implementation of
the vaccination program compared to those born
before the introduction of vaccination. In addi-
tion, the risk of having HBV markers of infection
was 7.26 times (95% CI, 5.05–10.44) higher in
subjects with a family history of hepatitis B.
Our study showed that the HBV carrier rate
dropped to 2.2% after the initiation of hepatitis
B immunization. Comparing the results between
freshmen born before and those after July 1984,
the HBsAg and anti-HBc positive rates decreased
by 70.3% and 71.5%, respectively. The HBsAg pos-
itive rate (7.4%) in this cohort was lower than
that of the general population (15–20%) and the
university study done by Liu et al (14.4%),17 re-
vealing the effectiveness (84.7%) of this program.
Despite the effectiveness of hepatitis B immuniza-
tion, natural infection of hepatitis B was still de-
tected (5.7%). The reasons may be incomplete
vaccination coverage, incomplete hepatitis B im-
munization doses, or poor response to hepatitis
B immunization.
The HBsAg positivity in this study (2.2%) was
lower than that of a 15-year-old cohort from a rural
township (11.4%)15 and a small city (4.1%),14
H.C. Chang, et al
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Table 2. Seroprevalence of hepatitis B viral markers for freshmen
Total (N = 7592) Before July 1984 (N=1204) After July 1984 (N = 6388)
n (%) 95% CI n (%) 95% CI n (%) 95% CI
p*
HBsAg < 0.001
Positive 229 (3.0) 2.6–3.4 89 (7.4) 5.9–8.9 140 (2.2) 1.8–2.6
Negative 7363 (97.0) 96.6–97.4 1115 (92.6) 91.3–94.1 6248 (97.8) 97.5–98.2
Anti-HBs
Positive 5577 (73.5) 72.5–74.5 832 (69.1) 66.5–71.7 4745 (74.3) 73.2–75.4 < 0.001
Anti-HBc(+) 457 (8.2) 7.5–8.9 187 (22.5) 19.6–25.3 270 (5.7) 5.0–6.4 < 0.001
Anti-HBc(–) 5120 (91.8) 91.1–92.5 645 (77.5) 74.7–80.4 4475 (94.3) 93.7–95.0
Negative 2015 (26.5) 25.6–27.5 372 (30.9) 28.3–33.5 1643 (25.7) 24.7–26.8
Anti-HBc < 0.001
Positive 708 (9.3) 8.7–10.0 283 (23.5) 21.1–25.9 425 (6.7) 6.0–7.3
Negative 6884 (90.7) 90.0–91.3 921 (76.5) 74.1–78.9 5963 (93.4) 92.7–94.0
Seronegative† 0.786
Yes 1757 (23.1) 22.2–24.1 275 (22.8) 20.5–25.2 1482 (23.2) 22.2–24.2
No 5835 (76.9) 75.9–77.8 929 (77.2) 74.8–75.9 4906 (76.8) 75.8–77.8
*c2 test; †seronegativity was defined as being negative for all three hepatitis B markers HBsAg, anti-HBs and anti-HBc.
but higher than that from an urban area (0.5%).13
The same trend in different areas could be seen
in anti-HBc seroprevalence. The difference in the
HBsAg positive rate may have several possible ex-
planations. First, the hepatitis B seroconversion
took place during these years, but this is unlikely
because immune clearance rate before 20 years
old was reported to be low.18 Second, the baseline
HBsAg positivity might be different among these
studies, but past study has shown a similar HBsAg
positivity and highly infectious rate of pregnant
mothers from different counties between 1984
and 1985.6 Third, different vaccine completion
rates, defined as receiving at least three doses of
hepatitis B vaccine, may contribute to these dif-
ferences. For this birth cohort, only those who
were born to HBsAg carrier mothers with positive
HBeAg or serum HBsAg titers ≥ 2560 received
vaccination at birth. Most of them received vacci-
nation in the preschool or school-age period as
the program extended. Since 67.4% of subjects
of this birth cohort in our study were positive for
anti-HBs and negative for anti-HBc, it might be
inferred that these subjects have previously re-
ceived hepatitis B immunization. Reviewing past
studies, the vaccine completion rate was 11.8% at
15 months old for all, 60.7% at 6 years old for
nationwide sampling, < 72% at 15 years old in
the rural area, and 80% at 15 years old in the
urban area in Taiwan. Therefore, the vaccine com-
pletion rate in different areas was the most likely
contributing factor to these differences.6,9,13,15
Subjects who are seronegative for all three HBV
serum markers are more susceptible to hepatitis B
infection. In our study, 21.8% of subjects who were
born after the vaccination program and had self-
reported hepatitis B vaccination history were still
seronegative. The possible explanations included
initial vaccination failure, decline in the efficacy
of vaccination with time, or recall bias. It brings to
attention the need for further booster shots and
the confirmation of hepatitis B viral markers. At
present, booster shots for waning immunity in fully
immunized individuals younger than 15 years 
of age are not necessary except in health care
workers or immunocompromised individuals.19,20
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Table 3. Multiple logistic regression analyses for the seropositivity of hepatitis B
OR 95% CI p
HBsAg(+)/HBsAg(–)
Sex Male/Female 1.08 0.76–1.52 0.68
Age Continuous variable 1.04 0.99–1.09 0.13
Birth year Before/After July 1984 2.06 1.30–3.27 0.002
Family history of hepatitis B* Yes/No 7.26 5.05–10.44 < 0.0001
Hepatitis B vaccination history Yes/No 0.24 0.16–0.37 < 0.0001
Anti-HBs(+)/Anti-HBs(–)
Sex Male/Female 0.70 0.62–0.79 < 0.0001
Age Continuous variable 1.00 0.98–1.04 0.77
Birth year Before/After July 1984 0.98 0.79–1.21 0.84
Family history of hepatitis B* Yes/No 0.63 0.52–0.77 < 0.0001
Hepatitis B vaccination history Yes/No 3.12 2.57–3.79 < 0.0001
Anti-HBc(+)/Anti-HBc(–)
Sex Male/Female 1.02 0.83–1.24 0.87
Age Continuous variable 1.13 1.09–1.18 < 0.0001
Birth year Before/After July 1984 1.96 1.48–2.62 < 0.0001
Family history of hepatitis B* Yes/No 4.07 3.18–5.21 < 0.0001
Hepatitis B vaccination history Yes/No 0.43 0.33–0.57 < 0.0001
*Family history of hepatitis B refers to any family members who have HBsAg positivity. OR = odds ratio; CI = confidence interval.
However, whether booster shots are needed for
subjects older than 15 years is still under debate.21
After controlling the variables including gen-
der, age, birth year, and hepatitis B vaccination
history, subjects with family history of hepatitis B
still had 7.26 (95% CI, 5.05–10.44) times higher
risk of being infected by hepatitis B and becoming
a carrier. Several studies suggested HBIG admin-
istration within 24 hours after birth for those
born to high-risk mothers to reduce this risk.22–24
Our results reinforced the importance of family
history of hepatitis B as an independent variable.
Further measures may be needed for those who
have family history of hepatitis B, such as early
check-up of hepatitis B status after complete vac-
cination or close follow up of their hepatitis B
status. HBV eradication or treatment to lower
HBV activity among pregnant women should be
considered, taking cost-effectiveness and safety
into account.
Some limitations of this study should be ad-
dressed. First, regarding the validity of vaccination
history or family history of hepatitis B, some recall
bias may have occurred since they were self-
reported data. However, since the questionnaires
were completed before the blood examinations,
the bias would have been non-differential. To di-
minish the potential recall bias of the vaccination
and family history of hepatitis B, we reminded
subjects to ask their parents for confirmation of
vaccination history and family history of hepati-
tis B. The status of family history of hepatitis B was
assumed to be stationary among the study sub-
jects due to limited age differences (mean age,
19.8 ± 2.7 years). We compared the data of family
history of hepatitis B between birth year before
July 1984 and after (Table 1). The results showed
no difference (8.8% vs. 8.7%), so the validity of
self-reported vaccination history can be assumed
to be good. Second, with regards to the relation-
ship between the concentration of anti-HBs titer
and HBV vaccination, there is limited quantitative
data on the anti-HBs titer in our study. Further
study regarding this part is needed.
In conclusion, this study provides the sero-
prevalence data of hepatitis B status 20 years after
the introduction of a mass vaccination program.
Whether seronegative cases need boosters deserves
further clinical trials to confirm. Those who have
a family history of hepatitis B may require closer
follow up of their hepatitis B status after hepati-
tis B vaccination.
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